Skip to main content
Top
Published in: Pathology & Oncology Research 1/2011

01-03-2011

The Probable Role of Tumor Stem Cells for Lymph Node Metastasis in Supraglottic Carcinoma

Authors: Sumei Lu, Jiajun Tian, Zhenghua Lv, Haibo Wang, Xiaohui Bai, Wenwen Liu, Jianfeng Li, Wei Xu

Published in: Pathology & Oncology Research | Issue 1/2011

Login to get access

Abstract

Tumor stem cells (TSC), which are considered as likely candidates for the origin of cancer, are deduced to be responsible for tumor metastasis theoretically. We therefore investigated whether TSC were associated with lymph node metastasis in supraglottic carcinoma. Immunohistochemistry was performed for CD44, CD133, and LYVE-1 to detect TSC and lymphatic vessel density (LVD) in 66 primary supraglottic carcinoma tissue samples from 30 patients with lymph node metastasis (N+) and 36 patients without (N0). Reverse transcriptase polymerase chain reaction (RT-PCR) and Western blot were used to detect the expression of CD44 and CD133 at mRNA and protein levels in N+ and N0 primary tumors. The LVD was 22.4 ± 10.26 in 30N+ and 6.8 ± 4.09 in 36N0 samples subjected to immunohistochemistry, which was associated with their clinical nodal stages. There were 43.33% CD44-positive and 93.33% CD133-positive samples in 30N+, and 13.89% CD44-positive and 44.44% CD133-positive samples in 36N0 (P < 0.05). However, in each positive slide, there were only 5∼10% CD44-positive cells, but 70∼85% CD133-possitive cells. The expressions of CD44 and CD133 of N+ obtained through RT-PCR and Western blot were significantly higher than those of N0. These results suggest that TSC identified through CD44-positive cells in N+ were significantly higher than those in N0, indicating that TSC may be responsible for lymph node metastasis. CD133, whose expression is not restricted to TSC, may be unspecific for TSC identification in hypostatic supraglottic carcinoma.
Literature
1.
go back to reference Kyzas PA, Geleff S, Batistatou A et al (2005) Evidence for lymphangiogenesis and its prognostic implications in head and neck squamous cell carcinoma. J Pathol 206(2):170–7PubMedCrossRef Kyzas PA, Geleff S, Batistatou A et al (2005) Evidence for lymphangiogenesis and its prognostic implications in head and neck squamous cell carcinoma. J Pathol 206(2):170–7PubMedCrossRef
2.
go back to reference Zhao D, Pan J, Li XQ et al (2008) Intratumoral lymphangiogenesis in oral squamous cell carcinoma and its clinicopathological significance. J Oral Pathol Med 37(10):616–25PubMedCrossRef Zhao D, Pan J, Li XQ et al (2008) Intratumoral lymphangiogenesis in oral squamous cell carcinoma and its clinicopathological significance. J Oral Pathol Med 37(10):616–25PubMedCrossRef
3.
go back to reference Dalerba P, Cho RW, Clarke MF (2007) Cancer stem cells: models and concepts. Annu Rev Med 58:267–84PubMedCrossRef Dalerba P, Cho RW, Clarke MF (2007) Cancer stem cells: models and concepts. Annu Rev Med 58:267–84PubMedCrossRef
5.
go back to reference Wicha MS, Liu S, Dontu G (2006) Cancer stem cells: an old idea: a paradigm shift. Cancer Res 66:1883–1890PubMedCrossRef Wicha MS, Liu S, Dontu G (2006) Cancer stem cells: an old idea: a paradigm shift. Cancer Res 66:1883–1890PubMedCrossRef
6.
go back to reference Pardal R, Clarke MF, Morrison SJ (2003) Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 3(12):895–902PubMedCrossRef Pardal R, Clarke MF, Morrison SJ (2003) Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 3(12):895–902PubMedCrossRef
7.
go back to reference Prince ME, Ailles LE (2008) Cancer stem cells in head and neck squamous cell cancer. J Clin Oncol 26(17):2871–5PubMedCrossRef Prince ME, Ailles LE (2008) Cancer stem cells in head and neck squamous cell cancer. J Clin Oncol 26(17):2871–5PubMedCrossRef
8.
go back to reference Ailles L, Prince M (2009) Cancer stem cells in head and neck squamous cell carcinoma. Methods Mol Biol 568:175–93PubMedCrossRef Ailles L, Prince M (2009) Cancer stem cells in head and neck squamous cell carcinoma. Methods Mol Biol 568:175–93PubMedCrossRef
9.
go back to reference Wei XD, Zhou L, Cheng L et al (2009) In vivo investigation of CD133 as a putative marker of cancer stem cells in Hep-2 cell line. Head and neck 31:94–101PubMedCrossRef Wei XD, Zhou L, Cheng L et al (2009) In vivo investigation of CD133 as a putative marker of cancer stem cells in Hep-2 cell line. Head and neck 31:94–101PubMedCrossRef
10.
go back to reference Audet N, Beasley NJ, MacMillan C et al (2005) Lymphatic vessel density, nodal metastases, and prognosis in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 131:1065–70PubMedCrossRef Audet N, Beasley NJ, MacMillan C et al (2005) Lymphatic vessel density, nodal metastases, and prognosis in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 131:1065–70PubMedCrossRef
11.
go back to reference Koskinen WJ, Bono P, Leivo I et al (2005) Lymphatic vessel density in vocal cord carcinomas assessed with LYVE-1 receptor expression. Radiother Oncol 77:172–5PubMedCrossRef Koskinen WJ, Bono P, Leivo I et al (2005) Lymphatic vessel density in vocal cord carcinomas assessed with LYVE-1 receptor expression. Radiother Oncol 77:172–5PubMedCrossRef
12.
go back to reference Gao P, Zhou GY, Yin G et al (2006) Lymphatic vessel density as a prognostic indicator for patients with stage I cervical carcinoma. Hum Pathol 37:719–25PubMedCrossRef Gao P, Zhou GY, Yin G et al (2006) Lymphatic vessel density as a prognostic indicator for patients with stage I cervical carcinoma. Hum Pathol 37:719–25PubMedCrossRef
13.
go back to reference Mori D, Yamasaki F, Shibaki M et al (2007) Lateral peritumoral lymphatic vessel invasion can predict lymph node metastasis in esophageal squamous cell carcinoma. Mod Pathol 20:694–700PubMedCrossRef Mori D, Yamasaki F, Shibaki M et al (2007) Lateral peritumoral lymphatic vessel invasion can predict lymph node metastasis in esophageal squamous cell carcinoma. Mod Pathol 20:694–700PubMedCrossRef
14.
go back to reference Maula SM, Luukkaa M, Grénman R et al (2003) Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res 63:1920–6PubMed Maula SM, Luukkaa M, Grénman R et al (2003) Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res 63:1920–6PubMed
15.
go back to reference Gao P, Zhou GY, Zhang QH et al (2008) Clinicopathological significance of peritumoral lymphatic vessel density in gastric carcinoma. Cancer Lett 263:223–230PubMedCrossRef Gao P, Zhou GY, Zhang QH et al (2008) Clinicopathological significance of peritumoral lymphatic vessel density in gastric carcinoma. Cancer Lett 263:223–230PubMedCrossRef
16.
go back to reference Wang J, Guo LP, Chen LZ et al (2007) Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res 67:3716–24PubMedCrossRef Wang J, Guo LP, Chen LZ et al (2007) Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res 67:3716–24PubMedCrossRef
17.
go back to reference Bianchini C, Ciorba A, Pelucchi S et al (2008) Head and neck cancer: the possible role of stem cells. Eur Arch Otorhinolaryngol 265:17–20PubMedCrossRef Bianchini C, Ciorba A, Pelucchi S et al (2008) Head and neck cancer: the possible role of stem cells. Eur Arch Otorhinolaryngol 265:17–20PubMedCrossRef
18.
go back to reference Harper LJ, Piper K, Common J et al (2007) Stem cell patterns in cell lines derived from head and neck squamous cell carcinoma. J Oral Pathol Med 36:594–603PubMedCrossRef Harper LJ, Piper K, Common J et al (2007) Stem cell patterns in cell lines derived from head and neck squamous cell carcinoma. J Oral Pathol Med 36:594–603PubMedCrossRef
19.
go back to reference Pries R, Witrkopf N, Trenkle T et al (2008) Potential stem cell marker CD44 is constitutively expressed in permanent cell lines of head and neck cancer. In Vivo 22:89–92PubMed Pries R, Witrkopf N, Trenkle T et al (2008) Potential stem cell marker CD44 is constitutively expressed in permanent cell lines of head and neck cancer. In Vivo 22:89–92PubMed
20.
go back to reference Wright MH, Calcagno AM, Salcido CD et al (2008) Brca1 breast tumors contain distinct CD44+/CD24−and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 10:R10PubMedCrossRef Wright MH, Calcagno AM, Salcido CD et al (2008) Brca1 breast tumors contain distinct CD44+/CD24−and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 10:R10PubMedCrossRef
21.
go back to reference Du L, Wang H, He L (2008) CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res 14(21):6751–60PubMedCrossRef Du L, Wang H, He L (2008) CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res 14(21):6751–60PubMedCrossRef
22.
go back to reference Zito G, Richiusa P, Bommarito A et al (2008) In vitro identification and characterization of CD133 (pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines. PLoS One 3:e3544PubMedCrossRef Zito G, Richiusa P, Bommarito A et al (2008) In vitro identification and characterization of CD133 (pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines. PLoS One 3:e3544PubMedCrossRef
23.
go back to reference Choi D, Lee HW, Hur KY et al (2009) Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol 15(18):2258–64PubMedCrossRef Choi D, Lee HW, Hur KY et al (2009) Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol 15(18):2258–64PubMedCrossRef
24.
go back to reference Griguer CE, Oliva CR, Gobin E et al (2008) CD133 is a marker of bioenergetic stress in human glioma. PLoS One 3(11):e3655PubMedCrossRef Griguer CE, Oliva CR, Gobin E et al (2008) CD133 is a marker of bioenergetic stress in human glioma. PLoS One 3(11):e3655PubMedCrossRef
25.
go back to reference Richardson GD, Robson CN, Lang SH et al (2004) CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 117:3539–45PubMedCrossRef Richardson GD, Robson CN, Lang SH et al (2004) CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 117:3539–45PubMedCrossRef
26.
go back to reference Olempska M, Eisenach PA, Ammerpohl O et al (2007) Detection of tumor stem cell markers in pancreatic carcinoma cell lines. Hepatobiliary Pancreat Dis Int 6:92–7PubMed Olempska M, Eisenach PA, Ammerpohl O et al (2007) Detection of tumor stem cell markers in pancreatic carcinoma cell lines. Hepatobiliary Pancreat Dis Int 6:92–7PubMed
27.
go back to reference Immervoll H, Hoem D, Sakariassen PØ et al (2008) Expression of the “stem cell marker” CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer 8:48PubMedCrossRef Immervoll H, Hoem D, Sakariassen PØ et al (2008) Expression of the “stem cell marker” CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer 8:48PubMedCrossRef
28.
go back to reference Shmelkov SV, Butler JM, Hooper AT et al (2008) CD133 expression is not restricted to stem cells, and both CD133+ and CD133−metastatic colon cancer cells initiate tumors. J Clin Invest 118:2111–2120PubMed Shmelkov SV, Butler JM, Hooper AT et al (2008) CD133 expression is not restricted to stem cells, and both CD133+ and CD133−metastatic colon cancer cells initiate tumors. J Clin Invest 118:2111–2120PubMed
Metadata
Title
The Probable Role of Tumor Stem Cells for Lymph Node Metastasis in Supraglottic Carcinoma
Authors
Sumei Lu
Jiajun Tian
Zhenghua Lv
Haibo Wang
Xiaohui Bai
Wenwen Liu
Jianfeng Li
Wei Xu
Publication date
01-03-2011
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 1/2011
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-010-9271-9

Other articles of this Issue 1/2011

Pathology & Oncology Research 1/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine